On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

From ASH Meeting on Hematologic Malignancies: Treating a Young Patient With Newly Diagnosed ALL

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

From ASH Meeting on Hematologic Malignancies: Treating Patients With AML With Mutations and Minimal...

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

From ASH Meeting on Hematologic Malignancies: Treating “Problematic” Cases of Polycythemia Vera

During their presentations, MHM speakers will be asking the audience how they would respond to patient cases. Audience members will vote live at the...

APR-246 Plus Azacitidine Is Associated With High Response Rates in MDS and AML

In a small phase IB/II trial presented at the 23rd Congress of the European Hematology Association, all four evaluable patients with TP53-mutant myelodysplastic syndromes...

Umbralisib Demonstrates Safety, Efficacy for Patients With Kinase Inhibitor–Intolerant CLL

According to a report presented at the 23rd Congress of the European Hematology Association, the phosphoinositide 3-kinase (PI3K) and casein kinase-1ε inhibitor umbralisib represents...

Tagraxofusp: A New Option for Blastic Plasmacytoid Dendritic Cell Neoplasm?

Treatment with tagraxofusp, an anti-CD123 targeted agent previously known as SL-401, appeared to be safe and effective for managing blastic plasmacytoid dendritic cell neoplasm...

CheckMate 205: Evaluating Nivolumab in Newly Diagnosed Hodgkin Lymphoma

In a study presented by Radhakrishnan Ramchandren, MD, at the 23rd Congress of the European Hematology Association, the four-drug regimen of nivolumab plus doxorubicin,...

Better Together: IDH Inhibitors Plus Azacitidine in Newly Diagnosed AML

Results from a phase Ib/II study presented at the 23rd Congress of the European Hematology Association suggest that combining an IDH inhibitor (ivosidenib or...

Cardiac Biomarkers Predict Quality of Life in Patients With Light-Chain Amyloidosis

In a study presented at the 23rd Congress of the European Hematology Association, researchers demonstrated a relationship between B-type natriuretic peptide (BNP) and N-terminal...

Combining Ibrutinib and Venetoclax Produces High MRD-Negative Rates in Treatment-Naïve CLL

The all-oral regimen of single-agent ibrutinib followed by combined ibrutinib and venetoclax increased the odds that patients with treatment-naïve chronic lymphocytic leukemia (CLL) will...
Advertisement

Current Issue

September 2018, Volume 4, Issue 11

View issue flipbook September 2018 Volume 4, Issue 11This issue features a look at research misconduct, a debate about whether chronic lymphocytic leukemia is curable, and...